Plasma Lipidomics of HIV-1 infected patients based on ultra performance liquid chromatography–mass spectrometry

Abstract

Acquired immune deficiency syndrome (AIDS) has been shown to not only attack the body's immune system but also to cause metabolic disorders. Highly active anti-retroviral therapy (HAART) is the main treatment for AIDS, but it can also affect the human metabolic system and cause metabolic disorders. In this study, we analyzed how AIDS and HAART alter human metabolism through an ultra performance liquid chromatography–mass spectrometry (UPLC-MS) lipidomics approach. Differential metabolites with significant changes were identified by multivariate statistical analysis. There were 44 significantly different metabolites detected in the healthy volunteers and HAART-naïve patients, and 61 significantly different metabolites detected in the healthy volunteers and patients under HAART. Screening for biomarkers based on the area under the receiver operating characteristic curve. In the healthy and untreated groups, Sphinganine was identified as potential biomarkers. In the healthy and treated groups, Psychosine and Sphinganine were identified as potential biomarkers. Sphinganine and Psychosine as biomarkers have a wide range of potential clinical applications. In psychiatric disorders and metabolic disorders they can provide new directions for early diagnosis, therapeutic monitoring, and prognostic assessment of diseases. Future studies will further explore the specific mechanisms and clinical application value of these biomarkers.